KYTX
Kyverna Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-0.69 EPS
Last earnings +7.8% on 2026-05-12
$8.44
▲ +2.93%$8.44▲ +157.32%
over 1Y
L $2.77EODHDH $10.78
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.9%
1W+2.9%
1M-1.7%
3M+8.2%
YTD-3.8%
1Y+157.3%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Buy
Conservative balance sheet (liabilities/equity 0.26x).
Return on equity -69.4% · latest
Kyverna Therapeutics, Inc. shows limited reported revenue, and -69.4% ROE.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$62.4M | -$143M | -$170M |
| Net income | -$60.4M | -$127M | -$161M |
| Diluted EPS | -$89.61 | -$3.33 | -$3.64 |
| Net margin | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$386M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-31.6%
FCF yield-30.1%
Quality & risk
ROIC (est.)-57.8%
Free cash flow-$154M
Total debt—
Net cash$124M
Piotroski F-Score1/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+39.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Shareholder vote2026-06-02
- 8-K Officer / director change2026-05-18
- 8-K Earnings results2026-05-12
- 10-Q Quarterly report2026-05-12
- 8-K Other event2026-05-04
- 8-K Reg FD disclosure2026-04-22
- 8-K Reg FD disclosure2026-04-22
- DEF 14A Proxy statement2026-04-13
- S-3 Shelf registration (potential raise)2026-03-26
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-05-272026-06-02open ↗4Period ending 2026-05-272026-05-29open ↗4Period ending 2026-05-272026-05-29open ↗4Period ending 2026-05-272026-05-29open ↗4Period ending 2026-05-272026-05-29open ↗4Period ending 2026-05-272026-05-29open ↗4Period ending 2026-05-182026-05-20open ↗3Period ending 2026-05-182026-05-20open ↗8-KPeriod ending 2026-05-142026-05-18open ↗10-QPeriod ending 2026-03-312026-05-12open ↗8-KPeriod ending 2026-05-122026-05-12open ↗4Period ending 2026-05-042026-05-06open ↗
Frequently asked
- Is Kyverna Therapeutics, Inc. (KYTX) a buy?
- KYTX currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.26x).
- What is Kyverna Therapeutics, Inc.'s quality score?
- KYTX scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001994702, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 6:08:39 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.